Meeting
2017 ASCO Annual Meeting
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p).
Authors
Nitin Jain
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Nitin Jain , Philip A. Thompson , Jan Andreas Burger , Gautam Borthakur , Prithviraj Bose , Zeev Estrov , Alessandra Ferrajoli , Varsha Gandhi , William Plunkett , Wanda Lopez , Hagop M. Kantarjian , Susan Mary O'Brien , Michael J. Keating , William G. Wierda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT02629809
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7522)
DOI
10.1200/JCO.2017.35.15_suppl.7522
Abstract #
7522
Poster Bd #
284
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Quality Care Symposium
What are the health care costs for chronic lymphocytic leukemia?
First Author: Matthew J. Matasar
Poster
2019 ASCO Annual Meeting
ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
First Author: Ian Flinn
Poster
2016 ASCO Quality Care Symposium
Real-world treatment patterns and health care resource utilization (HRU) among patients with chronic lymphocytic leukemia (CLL) by regimen.
First Author: Brad Schenkel
